期刊
CANCER LETTERS
卷 421, 期 -, 页码 127-134出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2018.02.011
关键词
NF-kappa B; Chemotherapy; Chemoresistance; Pancreatic cancer
类别
资金
- National Natural Science Foundation of China [81472327]
- Major State Basic Research Development Program of China (973 Program) [2014CB542300]
- National Science and Technology Support Program of China [2014BAI09B11]
- Chinese Academy Medical Science Innovation Fund for Medical Sciences [2016-I2M-1-001]
- Fundamental Research Funds for Central Universities [2017320027]
- PUMC Youth Fund
Pancreatic cancer is considered a lethal disease with a high mortality and an extremely low five-year survival rate. Chemotherapy plays a pivotal role in pancreatic cancer treatment both in an adjuvant setting after complete resection and in the case of unresectable metastatic disease. However, none of the available combination chemotherapy regimens has resulted in satisfactory survival outcomes. Recent studies have revealed that both constitutive and induced activation of nuclear factor kappa B (NF-kappa B) in pancreatic cancer cells are closely associated with cell proliferation, invasion, anti-apoptosis, inflammation, angiogenesis and chemotherapeutic resistance. Therefore, NF-kappa B inhibitors in combination with cytotoxic compounds have been reported as novel agents that improve chemotherapy sensitivity in pancreatic cancer. In this review, we outline recent developments in the understanding of the role of the NF-kappa B signaling pathway and its associated genes in the progression of pancreatic cancer and highlight some potentially effective strategies for pancreatic cancer treatment, (C) 2018 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据